© 2014, Academia Nacional de Medicina. All rights reserved. Melanoma has shown a greater increase in frequency as compared to other neoplasms, demonstrated by a 619[%] incidence increase in the USA from 1950 to the year 2000. Its treatment has always been a challenge, and once it has metastasized, there are no available curative regimens. In recent years considerable progress in the understanding of its pathophysiology and progression has been achieved; with the description of the genetic, molecular, and immunologic changes, new and specific drugs have been developed, with better response rates than conventional chemotherapy. Currently, a broad scope of therapeutic choices is available, although only eight are approved by the FDA. In the following literature review we present some of the better-known systemic treatment options for melanoma, from conventional chemotherapy, molecular (MAPK inhibitors) and immunomodulatory (interleukin-2, tumor necrosis factor alpha, cytotoxic T lymphocyte antigen-4 and programmed death-1 inhibitors) therapies, to miscellaneous options, among which are angiogenesis inhibitors, apoptosis modulators, vaccines, and radiotherapy.
|Number of pages||11|
|Journal||Gaceta Medica de Mexico|
|Publication status||Published - 1 Jan 2014|
All Science Journal Classification (ASJC) codes
Ayala-Cortés, A. S., Garza-Rodríguez, V., & Ocampo-Candiani, J. (2014). Updates in the treatment of advanced stage melanoma. Gaceta Medica de Mexico, 145-155. https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84922311597&origin=inward